Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a necrotizing small-vessel vasculitis with a tropism for the kidney and respiratory tract.1 Treatment of AAV requires prompt initiation of immunosuppression to mitigate irreversible organ damage and prevent death. Currently, the standard of care for induction of remission in patients with severe disease is cyclophosphamide or rituximab in combination with high-dose glucocorticoids.2 In the setting of aggressive rapidly progressive glomerulonephritis (RPGN) or pulmonary hemorrhage (PH), plasma exchange is often used to rapidly remove ANCAs.